RT Journal Article
SR Electronic
T1 Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.04.21249227
DO 10.1101/2021.01.04.21249227
A1 Talasaz, Azita H.
A1 Sadeghipour, Parham
A1 Kakavand, Hessam
A1 Aghakouchakzadeh, Maryam
A1 Kordzadeh-Kermani, Elaheh
A1 Van Tassell, Benjamin W.
A1 Gheymati, Azin
A1 Ariannejad, Hamid
A1 Hosseini, Seyed Hossein
A1 Jamalkhani, Sepehr
A1 Sholzberg, Michelle
A1 Monreal, Manuel
A1 Jimenez, David
A1 Piazza, Gregory
A1 Parikh, Sahil A.
A1 Kirtane, Ajay
A1 Eikelboom, John W.
A1 Connors, Jean M.
A1 Hunt, Beverley J.
A1 Konstantinides, Stavros V.
A1 Cushman, Mary
A1 Weitz, Jeffrey I.
A1 Stone, Gregg W.
A1 Krumholz, Harlan M.
A1 Lip, Gregory Y.H.
A1 Goldhaber, Samuel Z.
A1 Bikdeli, Behnood
YR 2021
UL http://medrxiv.org/content/early/2021/01/06/2021.01.04.21249227.abstract
AB Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/ACOVID-19coronavirus disease 2019DOACdirect oral anticoagulantDTIdirect thrombin inhibitorICUintensive care unitLMWHlow molecular weight heparinRCTrandomized controlled trialSARS-CoV-2severe acute respiratory syndrome coronavirus 2UFHunfractionated heparinVTEvenous thromboembolism